More on OTLK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.43 |
|
|||
| Open | $0.43 | ||||
| 52 Wk High | $0.03 | ||||
| 52 Wk Low | $0.01 | ||||
| Day High | $0.43 | ||||
| Day Low | $0.40 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,926,104 | ||||
- Form 8-K Outlook Therapeutics, For: Mar 05
- Outlook Therapeutics meets with FDA on bevacizumab drug approval
- Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
- Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
- Form 8-K Outlook Therapeutics, For: Feb 18
- Form 10-Q Outlook Therapeutics, For: Dec 31
- Form 8-K Outlook Therapeutics, For: Feb 17
- Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
- Form 8-K Outlook Therapeutics, For: Feb 11
- Outlook Therapeutics requests FDA meeting after drug rejection
Entities mentioned with OTLK
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- Maynard Um | View Related Stories »
- Earnings | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
